Pharmacist startup to lower drug prices joins Microsoft for Startups

Print Friendly, PDF & Email

TAMPA, Fla. – InView Analytics, the Microsoft for Startups Program, awarded support after a pitch from a 34-year-old independent pharmacy owner who had an innovative plan for eliminating pharmaceutical waste to lower prescription drug costs. InView’s cofounder, Dr. Alex Toth, has an ambitious goal: to bring down the costs of prescription medications while driving more traffic to to local independent and community pharmacies.

Over $5 billion worth of unused medications in unopened packs are discarded every year. InView identifies excess overstock and facilitates transactions between pharmacies, hospitals, clinics, and government-run healthcare facilities, reducing drug waste to lower consumer prices. The platform bridges the gap between prescribers, patience, and Rx Inventory, and its unified search API will provide new options to shop local for affordable overstock medications.

Microsoft for Startups is a global program meant to accelerate the development of high-potential B2B startups to help them grow at scale. InView will have exclusive access to Microsoft technology, mentorship from company professionals, and business support as a program member. InView will also get a clear path to sell alongside Microsoft and its other partners to meet short-term revenue goals and achieve its long-term vision of reducing healthcare costs.

“The service is projected to save state healthcare programs, pharmacies, and consumers between $80 million and $150 million annually by eliminating inefficiencies and waste, and we are incredibly excited to be among such a select group of companies from around the world chosen to join the Microsoft for Startups program,” said Co-Founder & CEO Jeremy Froehner.

“InView’s mission to break down the data silos between pharmacies, hospitals, clinics, and consumers is a good fit for our program and ecosystem,” Sally Frank, worldwide lead for health and life sciences at Microsoft for Startups said in a statement.



Comments are closed.